A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Vincristine
- Indications Haemangioendothelioma
- Focus Adverse reactions; Therapeutic Use
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2018 Planned primary completion date changed from 1 Jun 2021 to 1 Sep 2022.
- 31 Aug 2018 Biomarkers information updated